TABLE 1

Radioactivity of Blood Samples Obtained After ¹³¹I Intake

Patient no.	Indication	¹³¹I dose (MBq)	Delay (h)*	Measured dose rate (μSv/h) < 2.5^†	Surface activity (Bq/cm²) < 5^†	Activity (Bq) < 1,000,000^†
1	Graves’ disease	740	17	6	13.7	69,171
2	Graves’ disease	740	113	0.20	0.80	2,478
3	Multinodular goiter	1,110	89	1.50	1.60	22,166
4	Graves’ disease	1,850	17	2.30	2.30	38,380
5	Multinodular goiter	1,850	41	<0.01	1.20	4,314
6	Thyroid carcinoma	3,700	17	0.28	1.42	51,157
7	Thyroid carcinoma	3,700	41	2.60	1.20	51,966
8	Thyroid carcinoma	3,700	41	1.30	1.60	11,971
9	Thyroid carcinoma	3,700	41	1.30	1.60	13,617
10	Thyroid carcinoma	3,700	41	1.50	1.10	17,321
11	Thyroid carcinoma	3,700	41	1.50	2.10	12,949
12	Thyroid carcinoma	3,700	44	1.20	1.80	34,340
13	Thyroid carcinoma	3,700	89	1.50	2.20	27,594
14	Thyroid carcinoma	3,700	113	1.00	0.28	8,032
15	Thyroid carcinoma	3,700	113	1.30	1.50	11,315